NCT01909856View on ClinicalTrials.gov

The Efficacy and Safety of Palonosetron in Preventing the Gastrointestinal Reactions Induced by 3-day Highly Emetogenic Chemotherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

April 30, 2014

Study Completion Date

June 30, 2014

Conditions
Cancer
Interventions
DRUG

Palonosetron

Palonosetron 0.25mg d1,d3

DRUG

Granisetron

Granisetron 3mg d1-3

DRUG

Dexamethasone

Dexamethasone 10mg d1-3

DRUG

Cisplatin

3-day chemotherapy regimens including cisplatin, cisplatin: 25mg/m2 d1-3

Trial Locations (1)

430030

Tongji Hospital,Tongji Medical College, Huazhong University of Science and Technology, Wuhan

Sponsors
All Listed Sponsors
lead

Jiangsu Simcere Pharmaceutical Co., Ltd.

INDUSTRY

NCT01909856 - The Efficacy and Safety of Palonosetron in Preventing the Gastrointestinal Reactions Induced by 3-day Highly Emetogenic Chemotherapy | Biotech Hunter | Biotech Hunter